The 6 most recent market catalysts affecting $CUE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma released positive Phase 2 trial results for CUE-221, a drug for chronic spontaneous urticaria. The study met its primary and secondary endpoints, showing strong effic…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis
Cue Biopharma reported highly positive Phase 2 results for its drug candidate CUE-221 in chronic spontaneous urticaria, demonstrating a 60% complete hives resolution rate compared …
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83
B. Riley Securities analyst Mayank Mamtani has initiated coverage on Cue Biopharma (CUE) with a 'Buy' rating and a significant price target of $83. This event is a positive catalys…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 92
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma's Q2 earnings report presents a mixed picture, with a substantial miss on earnings per share (EPS) but a strong beat on sales. The EPS miss, at 1328.4% worse than est…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 55
Cue Biopharma Files Prospectus For Resale Of 1,505,570 Shares, Including 87,500 Underlying Pre-Funded Warrants, Issued In $50M July Private Placement
Cue Biopharma has filed a prospectus to register for resale 1,505,570 shares, including those underlying pre-funded warrants, that were issued in a $50 million private placement in…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 55
Cue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma has appointed James M. Ahlers as its new Chief Financial Officer. This appointment is significant as it occurs at a 'pivotal point' for the company, with a recent IND…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.